A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 9/127 (2006.01) A61K 31/132 (2006.01) A61K 31/704 (2006.01)
Patent
CA 2587470
The present invention concerns a new medical treatment involving the combination of two active entities, as well as pharmaceutical compositions comprising the two active entities. Specifically, the invention provides a pharmaceutical composition comprising a stable lipid assembly comprising as a first active entity an apoptosis-affecting lipid which does not self-aggregate in a polar environment to form liposomes and a lipopolymer. The pharmaceutical composition further comprises, as the second active entity, a cytotoxic amphipathic weak base drug carried by the lipid assembly or by a different liposome. According to one embodiment, the apoptotic-affecting lipid is a pro- apoptotic lipid. A preferred pro-apoptotic lipid is ceramide, preferably C6- ceramide. The cytotoxic amphipathic weak base drug is preferably doxorubicin or a biologically active, anthracyline-based doxorubicin analog thereof.
Nouveau traitement médical impliquant la combinaison de deux principes actifs, les compositions pharmaceutiques contenant les deux principes actifs. Plus spécifiquement, composition pharmaceutique comprenant une ensemble lipide stable utilisant comme premier principe actif un lipide affectant l'apoptose sans agrégat automatique dans un environnement polaire afin de former des liposomes et un lipopolymère. La composition pharmaceutique contient également, comme second principe actif, un médicament à faible base cytotoxique et amphipatique supporté par l'ensemble lipide ou par un liposome différent. Selon un mode de réalisation, le lipide affectant l'apoptose est un lipide pro-apoptotique. Un liquide pro-apoptotique préféré est un céramide, de préférence un céramide C6. Le médicament à faible base cytotoxique et amphipathique est de préférence une doxorubicine ou un analogue de doxorubicine à anthracyline biologiquement actif.
Barenholz Yechezkel
Khazanov Elena
Norton Rose Canada S.e.n.c.r.l.,s.r.l./llp
Yissum Research Development Company Of The Hebrew University Of
LandOfFree
Combination therapy associating preferably a ceramide with a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination therapy associating preferably a ceramide with a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy associating preferably a ceramide with a... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1454272